SLC33A1 and progeroid syndrome: When taken together, the above results indicate that inhibition of both ER-based ATases through Compound 9 does not only prevent the development or the exacerbation of disease phenotypes, as demonstrated in our previous study8; it also rescues ongoing severe disease manifestations of the AT-1 sTg progeria-like phenotype.